Clinical trial results:
A Randomized, Open-label, Multicenter, Multiphase Study of JNJ-63723283, an Anti-PD-1 Monoclonal Antibody, Administered in Combination with Daratumumab, Compared with Daratumumab Alone in Subjects with Relapsed or Refractory Multiple Myeloma

Summary

EudraCT number	2017-002611-34
Trial protocol	BE ES FR GR
Global end of trial date	19 November 2021

Results information

Result version number	v1 (current)
This version publication date	15 December 2022
First version publication date	15 December 2022

Trial information

Trial identification

Sponsor protocol code	54767414MMY2036

Additional study identifiers

ISRCTN number	-
ClinicalTrials.gov id (NCT number)	NCT03357952
WHO universal trial number (UTN)	-

Notes:

Sponsors

Sponsor organisation name	Janssen Research & Development, LLC
Sponsor organisation address	920 US Highway 202, Raritan, NJ, United States, 08869-1420
Public contact	Clinical Registry Group, Janssen Research & Development, LLC, ClinicalTrialsEU@its.jnj.com
Scientific contact	Clinical Registry Group, Janssen Research & Development, LLC, ClinicalTrialsEU@its.jnj.com

Notes:

Paediatric regulatory details

Is trial part of an agreed paediatric investigation plan (PIP)	No
Does article 45 of REGULATION (EC) No 1901/2006 apply to this trial?	No
Does article 46 of REGULATION (EC) No 1901/2006 apply to this trial?	No

Notes:

Results analysis stage

Analysis stage	Final
Date of interim/final analysis	16 January 2019
Is this the analysis of the primary completion data?	No

Global end of trial reached?	Yes
Global end of trial date	19 November 2021
Was the trial ended prematurely?	No

Notes:

General information about the trial

Main objective of the trial:

The main objective of this trial was to assess the safety of the combination of JNJ-63723283 and daratumumab and to compare the overall response rate (ORR) in subjects treated with JNJ-63723283 in combination with daratumumab versus daratumumab alone.

Protection of trial subjects:

This study was conducted in accordance with the ethical principles that have their origin in the Declaration of Helsinki and that are consistent with Good Clinical Practices and applicable regulatory requirements.

Background therapy: -

Evidence for comparator: -

Actual start date of recruitment	16 November 2017
Long term follow-up planned	No
Independent data monitoring committee (IDMC) involvement?	Yes

Notes:

Population of trial subjects

Subjects enrolled per country

Country: Number of subjects enrolled	Belgium: 4
Country: Number of subjects enrolled	Spain: 1
Country: Number of subjects enrolled	Israel: 5
Worldwide total number of subjects	10
EEA total number of subjects	5

Notes:

Subjects enrolled per age group

In utero	0
Preterm newborn - gestational age < 37 wk	0
Newborns (0-27 days)	0
Infants and toddlers (28 days-23 months)	0
Children (2-11 years)	0
Adolescents (12-17 years)	0
Adults (18-64 years)	6
From 65 to 84 years	4

85 years and over	0

Subject disposition

Recruitment

Recruitment details: -

Pre-assignment

Screening details:

A total of 10 subjects were enrolled in the study. Among these, 9 subjects were included in the Safety Run-in phase (Part 1) who received daratumumab intravenous (IV) and JNJ-63723283 IV and 1 subject randomised to Arm A in Part 2 of the study who received daratumumab IV alone.

Period 1

Period 1 title	Overall Study (overall period)
Is this the baseline period?	Yes
Allocation method	Randomised - controlled
Blinding used	Not blinded

Arms

Are arms mutually exclusive?	Yes
Arm title	Part 1: Daratumumab + JNJ-63723283

Arm description:

Subjects in safety run-in cohort received daratumumab 16 milligram per kilogram (mg/kg) intravenously (IV) once every week (Weeks 1 to 8); then once every other week for 16 weeks (Weeks 9 to 24); then once every 4 weeks (Week 25 onwards) and JNJ-63723283 240 milligram (mg) IV during Week 1 on Cycle 1 Day 2, Cycle 1 Day 15, then every 2 weeks thereafter. Each treatment cycle consisted of 28 days. Subjects continued to receive study treatment until confirmed disease progression, unacceptable toxicity, or any other treatment discontinuation criteria were met.

Arm type	Active comparator
Investigational medicinal product name	Daratumumab
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Infusion
Routes of administration	Intravenous use

Dosage and administration details:

Subjects received daratumumab 16 mg/kg IV once every week (Weeks 1 to 8); then once every other week for 16 weeks (Weeks 9 to 24); then once every 4 weeks (Week 25 onwards).

Investigational medicinal product name	JNJ-63723283
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Infusion
Routes of administration	Intravenous use

Dosage and administration details:

Subjects received JNJ-63723283 240 mg IV during Week 1 on Cycle 1 Day 2, Cycle 1 Day 15, then every 2 weeks thereafter. Each treatment cycle consisted of 28 days.

Arm title	Part 2: Daratumumab (Arm A)

Arm description:

Subjects in treatment Arm A received daratumumab 16 mg/kg IV once every week (Weeks 1 to 8); then once every other week for 16 weeks (Weeks 9 to 24); then once every 4 weeks (Week 25 onwards). All subjects were continued to receive study treatment until confirmed disease progression, unacceptable toxicity, or any other treatment discontinuation criteria were met.

Arm type	Active comparator

Investigational medicinal product name	Daratumumab
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Dispersion for infusion, Infusion
Routes of administration	Intravenous use

Dosage and administration details:

Subjects in treatment Arm A received daratumumab 16 mg/kg IV once every week (Weeks 1 to 8); then once every other week for 16 weeks (Weeks 9 to 24); then once every 4 weeks (Week 25 onwards).

Number of subjects in period 1	Part 1: Daratumumab + JNJ-63723283	Part 2: Daratumumab (Arm A)
Started	9	1
Completed	0	0
Not completed	9	1
Sponsor Decision	9	-
Withdrawal by Subject	-	1

Baseline characteristics

Reporting groups

Reporting group title	Part 1: Daratumumab + JNJ-63723283

Reporting group description:

Subjects in safety run-in cohort received daratumumab 16 milligram per kilogram (mg/kg) intravenously (IV) once every week (Weeks 1 to 8); then once every other week for 16 weeks (Weeks 9 to 24); then once every 4 weeks (Week 25 onwards) and JNJ-63723283 240 milligram (mg) IV during Week 1 on Cycle 1 Day 2, Cycle 1 Day 15, then every 2 weeks thereafter. Each treatment cycle consisted of 28 days. Subjects continued to receive study treatment until confirmed disease progression, unacceptable toxicity, or any other treatment discontinuation criteria were met.

Reporting group title	Part 2: Daratumumab (Arm A)

Reporting group description:

Subjects in treatment Arm A received daratumumab 16 mg/kg IV once every week (Weeks 1 to 8); then once every other week for 16 weeks (Weeks 9 to 24); then once every 4 weeks (Week 25 onwards). All subjects were continued to receive study treatment until confirmed disease progression, unacceptable toxicity, or any other treatment discontinuation criteria were met.

Reporting group values	Part 1: Daratumumab + JNJ-63723283	Part 2: Daratumumab (Arm A)	Total
Number of subjects	9	1	10
Title for AgeCategorical Units: subjects			
Children (2-11 years)	0	0	0
Adolescents (12-17 years)	0	0	0
Adults (18-64 years)	5	1	6
From 65 to 84 years	4	0	4
85 years and over	0	0	0
Title for AgeContinuous			
Here, '99999' indicated standard deviation could not be calculated for 1 subject.			
Units: years			
arithmetic mean	63	43	
standard deviation	± 10.97	± 99999	-
Title for Gender Units: subjects			
Female	4	0	4
Male	5	1	6

End points

End points reporting groups

Reporting group title	Part 1: Daratumumab + JNJ-63723283

Reporting group description:

Subjects in safety run-in cohort received daratumumab 16 milligram per kilogram (mg/kg) intravenously (IV) once every week (Weeks 1 to 8); then once every other week for 16 weeks (Weeks 9 to 24); then once every 4 weeks (Week 25 onwards) and JNJ-63723283 240 milligram (mg) IV during Week 1 on Cycle 1 Day 2, Cycle 1 Day 15, then every 2 weeks thereafter. Each treatment cycle consisted of 28 days. Subjects continued to receive study treatment until confirmed disease progression, unacceptable toxicity, or any other treatment discontinuation criteria were met.

Reporting group title	Part 2: Daratumumab (Arm A)

Reporting group description:

Subjects in treatment Arm A received daratumumab 16 mg/kg IV once every week (Weeks 1 to 8); then once every other week for 16 weeks (Weeks 9 to 24); then once every 4 weeks (Week 25 onwards). All subjects were continued to receive study treatment until confirmed disease progression, unacceptable toxicity, or any other treatment discontinuation criteria were met.

Primary: Number of Subjects With Treatment Emergent Adverse Events (TEAE) in Safety run-in Phase (Part 1)

End point title	Number of Subjects With Treatment Emergent Adverse Events (TEAE) in Safety run-in Phase (Part 1)[1][2]

End point description:

An adverse event is any untoward medical event that occurs in a subject administered an investigational product, and it does not necessarily indicate only events with clear causal relationship with the relevant investigational product. TEAEs are adverse events (AEs) which will occur up to 2 years that were absent before treatment or that worsened relative to pre-treatment state. Safety analysis set included all subjects who received at least 1 dose of study agent (JNJ-63723283 or daratumumab, partial or complete) in safety run-in phase of the study.

End point type	Primary

End point timeframe:

Up to 2 years

Notes:

[1] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.
Justification: Descriptive statistics was done, no inferential statistical analysis was performed.

[2] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.
Justification: Endpoint was planned to be analyzed for specified arms only.

End point values	Part 1: Daratumumab + JNJ-63723283			
Subject group type	Reporting group			
Number of subjects analysed	9			
Units: Subjects	1			

Statistical analyses

No statistical analyses for this end point

Primary: Number of Subjects With Dose Limiting Toxicity in Safety run-in Phase (Part 1)

End point title	Number of Subjects With Dose Limiting Toxicity in Safety run-in Phase (Part 1)[3][4]

End point description:

Dose limiting toxicity defined as an adverse event or adverse drug reaction experienced by the subjects during observation of 28 days (Part 1) of treatment Cycle 1. Safety analysis set included all subjects who received at least 1 dose of study agent (JNJ-63723283 or daratumumab, partial or complete) in safety run-in phase.

End point type	Primary

End point timeframe:

Cycle 1 (28 days)

Notes:

[3] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.
Justification: Descriptive statistics was done, no inferential statistical analysis was performed.

[4] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.
Justification: Endpoint was planned to be analyzed for specified arms only.

End point values	Part 1: Daratumumab + JNJ-63723283			
Subject group type	Reporting group			
Number of subjects analysed	9			
Units: Subjects	0			

Statistical analyses

No statistical analyses for this end point

Secondary: Number of Subjects With Treatment Emergent Adverse Events (TEAE) in Part 2

End point title	Number of Subjects With Treatment Emergent Adverse Events (TEAE) in Part 2[5]

End point description:

An adverse event is any untoward medical event that occurs in a subject administered an investigational product, and it does not necessarily indicate only events with clear causal relationship with the relevant investigational product. TEAEs are adverse events (AEs) which will occur up to 2 years that were absent before treatment or that worsened relative to pre-treatment state. Safety analysis set included all subjects who received at least 1 dose of study agent in Part 2 of the study.

End point type	Secondary

End point timeframe:

Up to 2 years

Notes:

[5] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.
Justification: Endpoint was planned to be analyzed for specified arms only.

End point values	Part 2: Daratumumab (Arm A)			
Subject group type	Reporting group			
Number of subjects analysed	1			
Units: Subjects	1			

Statistical analyses

No statistical analyses for this end point

Adverse events

Adverse events information	
Timeframe for reporting adverse events:	
Up to 2 years	
Assessment type	Non-systematic

Dictionary used	
Dictionary name	MedDRA
Dictionary version	21.0

Reporting groups	
Reporting group title	Part 1: Daratumumab + JNJ-63723283

Reporting group description:

Subjects in safety run-in cohort received daratumumab 16 mg/kg IV once every week (Weeks 1 to 8); then once every other week for 16 weeks (Weeks 9 to 24); then once every 4 weeks (Week 25 onwards) and JNJ-63723283 240 milligram (mg) IV during Week 1 on Cycle 1 Day 2, Cycle 1 Day 15, then every 2 weeks thereafter. Each treatment cycle consisted of 28 days. Subjects continued to receive study treatment until confirmed disease progression, unacceptable toxicity, or any other treatment discontinuation criteria were met.

Reporting group title	Part 2: Daratumumab (Arm A)

Reporting group description:

Subjects in treatment Arm A received daratumumab 16 mg/kg IV once every week (Weeks 1 to 8); then once every other week for 16 weeks (Weeks 9 to 24); then once every 4 weeks (Week 25 onwards). All subjects were continued to receive study treatment until confirmed disease progression, unacceptable toxicity, or any other treatment discontinuation criteria were met.

Serious adverse events	Part 1: Daratumumab + JNJ-63723283	Part 2: Daratumumab (Arm A)	
Total subjects affected by serious adverse events			
subjects affected / exposed	3 / 9 (33.33%)	0 / 1 (0.00%)	
number of deaths (all causes)	0	0	
number of deaths resulting from adverse events			
Nervous system disorders			
Encephalitis Autoimmune			
subjects affected / exposed	1 / 9 (11.11%)	0 / 1 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Blood and lymphatic system disorders			
Febrile Neutropenia			
subjects affected / exposed	1 / 9 (11.11%)	0 / 1 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Renal and urinary disorders			
Acute Kidney Injury			

subjects affected / exposed	1 / 9 (11.11%)	0 / 1 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Infections and infestations			
Septic Shock			
subjects affected / exposed	1 / 9 (11.11%)	0 / 1 (0.00%)	
occurrences causally related to treatment / all	0 / 2	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	

Frequency threshold for reporting non-serious adverse events: 5 %

Non-serious adverse events	Part 1: Daratumumab + JNJ-63723283	Part 2: Daratumumab (Arm A)	
Total subjects affected by non-serious adverse events			
subjects affected / exposed	9 / 9 (100.00%)	1 / 1 (100.00%)	
Vascular disorders			
Hypertension			
subjects affected / exposed	2 / 9 (22.22%)	0 / 1 (0.00%)	
occurrences (all)	2	0	
General disorders and administration site conditions			
Asthenia			
subjects affected / exposed	2 / 9 (22.22%)	0 / 1 (0.00%)	
occurrences (all)	2	0	
Chills			
subjects affected / exposed	2 / 9 (22.22%)	0 / 1 (0.00%)	
occurrences (all)	2	0	
Oedema Peripheral			
subjects affected / exposed	1 / 9 (11.11%)	0 / 1 (0.00%)	
occurrences (all)	1	0	
Influenza Like Illness			
subjects affected / exposed	1 / 9 (11.11%)	0 / 1 (0.00%)	
occurrences (all)	1	0	
Fatigue			
subjects affected / exposed	3 / 9 (33.33%)	0 / 1 (0.00%)	
occurrences (all)	5	0	
Pyrexia			

subjects affected / exposed	1 / 9 (11.11%)	0 / 1 (0.00%)	
occurrences (all)	1	0	
Respiratory, thoracic and mediastinal disorders			
Cough			
subjects affected / exposed	2 / 9 (22.22%)	0 / 1 (0.00%)	
occurrences (all)	3	0	
Dysphonia			
subjects affected / exposed	1 / 9 (11.11%)	0 / 1 (0.00%)	
occurrences (all)	1	0	
Dyspnoea			
subjects affected / exposed	1 / 9 (11.11%)	0 / 1 (0.00%)	
occurrences (all)	1	0	
Rhinitis Allergic			
subjects affected / exposed	1 / 9 (11.11%)	0 / 1 (0.00%)	
occurrences (all)	1	0	
Throat Irritation			
subjects affected / exposed	1 / 9 (11.11%)	0 / 1 (0.00%)	
occurrences (all)	1	0	
Epistaxis			
subjects affected / exposed	1 / 9 (11.11%)	0 / 1 (0.00%)	
occurrences (all)	1	0	
Investigations			
Lipase Increased			
subjects affected / exposed	1 / 9 (11.11%)	0 / 1 (0.00%)	
occurrences (all)	3	0	
Weight Decreased			
subjects affected / exposed	1 / 9 (11.11%)	0 / 1 (0.00%)	
occurrences (all)	1	0	
Cardiac disorders			
Bradycardia			
subjects affected / exposed	1 / 9 (11.11%)	0 / 1 (0.00%)	
occurrences (all)	2	0	
Nervous system disorders			
Paraesthesia			
subjects affected / exposed	2 / 9 (22.22%)	0 / 1 (0.00%)	
occurrences (all)	2	0	

Dizziness			
subjects affected / exposed	1 / 9 (11.11%)	0 / 1 (0.00%)	
occurrences (all)	1	0	
Blood and lymphatic system disorders			
Anaemia			
subjects affected / exposed	3 / 9 (33.33%)	0 / 1 (0.00%)	
occurrences (all)	4	0	
Leukopenia			
subjects affected / exposed	1 / 9 (11.11%)	0 / 1 (0.00%)	
occurrences (all)	1	0	
Lymphopenia			
subjects affected / exposed	2 / 9 (22.22%)	0 / 1 (0.00%)	
occurrences (all)	12	0	
Neutropenia			
subjects affected / exposed	4 / 9 (44.44%)	0 / 1 (0.00%)	
occurrences (all)	13	0	
Thrombocytopenia			
subjects affected / exposed	3 / 9 (33.33%)	1 / 1 (100.00%)	
occurrences (all)	18	1	
Ear and labyrinth disorders			
Vertigo			
subjects affected / exposed	1 / 9 (11.11%)	0 / 1 (0.00%)	
occurrences (all)	1	0	
Eye disorders			
Corneal Degeneration			
subjects affected / exposed	1 / 9 (11.11%)	0 / 1 (0.00%)	
occurrences (all)	1	0	
Gastrointestinal disorders			
Constipation			
subjects affected / exposed	1 / 9 (11.11%)	0 / 1 (0.00%)	
occurrences (all)	1	0	
Diarrhoea			
subjects affected / exposed	2 / 9 (22.22%)	0 / 1 (0.00%)	
occurrences (all)	2	0	
Nausea			
subjects affected / exposed	3 / 9 (33.33%)	0 / 1 (0.00%)	
occurrences (all)	3	0	

Dyspepsia			
subjects affected / exposed	1 / 9 (11.11%)	0 / 1 (0.00%)	
occurrences (all)	1	0	
Dry Mouth			
subjects affected / exposed	1 / 9 (11.11%)	0 / 1 (0.00%)	
occurrences (all)	1	0	
Vomiting			
subjects affected / exposed	3 / 9 (33.33%)	0 / 1 (0.00%)	
occurrences (all)	4	0	
Skin and subcutaneous tissue disorders			
Pruritus			
subjects affected / exposed	1 / 9 (11.11%)	0 / 1 (0.00%)	
occurrences (all)	1	0	
Renal and urinary disorders			
Proteinuria			
subjects affected / exposed	1 / 9 (11.11%)	0 / 1 (0.00%)	
occurrences (all)	1	0	
Musculoskeletal and connective tissue disorders			
Back Pain			
subjects affected / exposed	1 / 9 (11.11%)	0 / 1 (0.00%)	
occurrences (all)	1	0	
Myalgia			
subjects affected / exposed	3 / 9 (33.33%)	0 / 1 (0.00%)	
occurrences (all)	3	0	
Musculoskeletal Pain			
subjects affected / exposed	1 / 9 (11.11%)	0 / 1 (0.00%)	
occurrences (all)	1	0	
Muscle Spasms			
subjects affected / exposed	1 / 9 (11.11%)	0 / 1 (0.00%)	
occurrences (all)	1	0	
Muscle Atrophy			
subjects affected / exposed	1 / 9 (11.11%)	0 / 1 (0.00%)	
occurrences (all)	1	0	
Myopathy			
subjects affected / exposed	1 / 9 (11.11%)	0 / 1 (0.00%)	
occurrences (all)	1	0	

Infections and infestations			
Rhinitis			
subjects affected / exposed	1 / 9 (11.11%)	0 / 1 (0.00%)	
occurrences (all)	1	0	
Osteomyelitis			
subjects affected / exposed	1 / 9 (11.11%)	0 / 1 (0.00%)	
occurrences (all)	7	0	
Herpes Simplex			
subjects affected / exposed	1 / 9 (11.11%)	0 / 1 (0.00%)	
occurrences (all)	1	0	
Cellulitis			
subjects affected / exposed	1 / 9 (11.11%)	0 / 1 (0.00%)	
occurrences (all)	1	0	
Body Tinea			
subjects affected / exposed	1 / 9 (11.11%)	0 / 1 (0.00%)	
occurrences (all)	2	0	
Upper Respiratory Tract Infection			
subjects affected / exposed	1 / 9 (11.11%)	0 / 1 (0.00%)	
occurrences (all)	1	0	
Vulvovaginal Candidiasis			
subjects affected / exposed	1 / 9 (11.11%)	0 / 1 (0.00%)	
occurrences (all)	1	0	
Viral Upper Respiratory Tract Infection			
subjects affected / exposed	1 / 9 (11.11%)	0 / 1 (0.00%)	
occurrences (all)	1	0	
Metabolism and nutrition disorders			
Hyperamylasaemia			
subjects affected / exposed	1 / 9 (11.11%)	0 / 1 (0.00%)	
occurrences (all)	2	0	
Folate Deficiency			
subjects affected / exposed	1 / 9 (11.11%)	0 / 1 (0.00%)	
occurrences (all)	1	0	
Dehydration			
subjects affected / exposed	1 / 9 (11.11%)	0 / 1 (0.00%)	
occurrences (all)	1	0	
Hyperglycaemia			

subjects affected / exposed	1 / 9 (11.11%)	0 / 1 (0.00%)	
occurrences (all)	1	0	
Hypomagnesaemia			
subjects affected / exposed	1 / 9 (11.11%)	0 / 1 (0.00%)	
occurrences (all)	1	0	

More information

Substantial protocol amendments (globally)

Were there any global substantial amendments to the protocol? Yes

Date	Amendment
23 August 2017	Revised DLT criteria • Revised eligibility criterion for recovery from toxicity from previous immunotherapy treatment • Added a criterion for dose delay due to non-immune-related adverse events (AEs). • The split first dose of daratumumab was replaced with the full daratumumab 16 milligrams per kilogram (mg/kg) regimen. • Clarified that communication with health authorities will occur before proceeding to Part 3. • Added a new section regarding study termination for safety considerations.
20 June 2018	On 25 May 2018, the sponsor stopped further enrollment into this study, Study 54767414MMY2036, based on safety and efficacy findings in the Study 54767414LUC2001, which combined daratumumab with atezolizumab in non-small cell lung cancer. At the third planned DMC review on 23 May 2018, the DMC reviewed the subject data for the Study 54767414LUC2001. The data monitoring committee (DMC) determined that there was no observed benefit in combination treatment arm (daratumumab+atezolizumab) over atezolizumab alone and recommended stopping enrollment of the study. In addition, the DMC recommended discontinuation of daratumumab treatment to all subjects receiving combination therapy (subjects randomized to the combination Arm B, and subjects randomized to Arm A who had crossed over into Arm B). Although no unexpected imbalances in on-treatment toxicities were observed, the DMC noted a clear early difference in number of deaths between atezolizumab monotherapy arm and combination arm. Discrepancy was observed within first 3 months of start of treatment, where the number of deaths were 4 in the atezolizumab arm and 10 in the combination arm, giving rise to 3-month survival rates of 90.7 percent (%) for the atezolizumab arm and 76.2% for the combination arm. Since the benefit/risk ratio changed for combination therapy in Study 54767414LUC2001, sponsor decided to suspend enrollment into other studies that combine daratumumab and a programmed death-1 (PD-1) or programmed death-ligand 1 (PD-L1) monoclonal antibody (mAb) regardless of indication. In addition to discontinuing enrollment in this study, treatment with the combination of daratumumab and JNJ-63723283 was discontinued and ongoing subjects were given the option to continue on daratumumab monotherapy until subject met one or more of the treatment discontinuation criteria. Assessments and data collection for the new daratumumab monotherapy period were defined and a window for End-of-Treatment (EOT) visit was added.
28 April 2020	The overall reason for the amendment was to provide flexibility for study investigators to prioritize the safety of their subjects during the global coronavirus (COVID-19) pandemic. To ensure continuity of study treatment, while limiting subjects' time spent at the study center, for subjects who will continue to receive daratumumab intravenous (IV), the duration of infusion may be shortened starting in Cycle 2 onwards to a 90-minute infusion for subjects without a history of an infusion related reaction after the third dose, at the discretion of the investigator. Detailed information regarding daratumumab IV administration, including infusion rates and duration, is removed and will be provided only in the Site Investigational Product Procedures Manual (SIPPM)'.

Notes:

Interruptions (globally)

Were there any global interruptions to the trial? No

Limitations and caveats

Limitations of the trial such as small numbers of subjects analysed or technical problems leading to unreliable data.

1 subject enrolled in Part 2 was not evaluable for efficacy, pharmacokinetics (pk) and immunogenicity endpoints. Hence, these endpoints were not collected. Sponsor suspended enrollment in Part 2 and stopped it early. Part 3 was not conducted.

Notes: